QIAGEN NV

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0015001WM6
USD
47.08
0.26 (0.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About QIAGEN NV stock-summary
stock-summary
QIAGEN NV
Pharmaceuticals & Biotechnology
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Coordinates stock-summary
Company Details
Hulsterweg 82 , VENLO None : 5912 PL
stock-summary
Tel: 31 77 355660031 773 556666
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 83 Schemes (31.94%)

Foreign Institutions

Held by 225 Foreign Institutions (29.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lawrence Rosen
Independent Chairman of the Supervisory Board
Mr. Stephane Bancel
Independent Member of the Supervisory Board
Dr. Metin Colpan
Independent Member of the Supervisory Board
Prof. Dr. Ross Levine
Independent Member of the Supervisory Board
Dr. Elaine Mardis
Independent Member of the Supervisory Board
Ms. Elizabeth Tallett
Independent Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
534 Million
(Quarterly Results - Jun 2025)
Net Profit:
96 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,429 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.83%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

12.29%

stock-summary
Price to Book

2.98